摘要
目的通过医院卫生技术评估(HB-HTA)对5种二肽基肽酶4抑制剂(DPP-4i)(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)进行评估,为医疗机构药品的遴选、临床的合理安全使用提供依据。方法通过HB-HTA,依照百分制评分体系,参考药品说明书、临床指南和文献,从安全性、有效性、经济型、创新性、适宜性和可及性等方面分别对5种DPP-4i进行评估。结果西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀得分分别为85.0、75.0、77.0、80.0、78.5分。评分差异主要在安全性、经济性、适宜性和可及性方面。西格列汀综合得分最高。结论HB-HTA评估DPP-4i结果比较合理,为医院药品遴选、安全合理使用提供依据。
Objective Five dipeptidyl peptidase 4 inhibitors(DPP-4i)(sitagliptin,vildagliptin,saxagliptin,linagliptin and alogliptin)were evaluated through hospital-based health technology assessment(HB-HTA)in order to provide basis for drug selection and clinical rational use in medical institutions.Methods Through HB-HTA,five types of DPP-4i were evaluated in terms of safety,efficacy,economy,innovation,suitability and accessibility based on a percentage scoring system,referring to drug instructions,clinical guidelines,and literature.Results The scores of siagliptin,vigagliptin,sagagliptin,ligagliptin and agragliptin were 85.0,75.0,77.0,80.0 and 78.5,respectively.The main differences in ratings were in terms of safety,economy,suitability and accessibility.Sigliptin had the highest overall score.Conclusion The HB-HTA evaluation of DPP-4i is relatively reasonable,providing a basis for hospital drug selection and safe and reasonable use.
作者
张俊珂
王晓娟
鲁憬莉
张瑞
郝洁
ZHANG Junke;WANG Xiaojuan;LU Jingli;ZHANG Rui;HAO Jie(Department of Pharmacy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《河南医学研究》
CAS
2024年第4期614-620,共7页
Henan Medical Research
基金
国家自然科学基金(82073860)。
